CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
about
Oncogenes: The Passport for Viral Oncolysis Through PKR InhibitionOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeViro-immune therapy: A new strategy for treatment of pancreatic cancerEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsOncolytic virotherapy for human malignant mesothelioma: recent advancesMeasles to the Rescue: A Review of Oncolytic Measles VirusTrial Watch-Oncolytic viruses and cancer therapyOncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancerHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsPolymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesCooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma ModelsOncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Gene and cell therapy for pancreatic cancer.Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.Oncolysis by paramyxoviruses: preclinical and clinical studies.How to develop viruses into anticancer weapons.Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMACombination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesAssessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.Arming oncolytic viruses to leverage antitumor immunity.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.Immunological landscape and immunotherapy of hepatocellular carcinoma.Fighting Cancer with Mathematics and Viruses.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.Targeting Melanoma with Cancer-Killing Viruses.A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.In situ vaccination for the treatment of cancer.State of play and clinical prospects of antibody gene transfer.
P2860
Q26739777-5F6236F9-C6ED-4D59-BD66-E6BE93AE74ECQ26769977-D2D7F86C-93E2-44E8-9A11-5A13E18DB929Q26774641-B3E7FC5C-60F7-4B06-8131-CE8662D38E79Q26775030-5E6E76AE-28D0-424D-AB12-EA1AA7CD4AAAQ26776553-BB8BD715-6B90-43FB-BBDE-5B5368F50D6AQ26826590-425C8DEC-4417-4055-94C0-D09A0BEE90D3Q28072097-9EB1787F-82D0-4EBB-96BC-F3EA6AAA2748Q28072347-D5EDFF80-2E07-4081-AC40-82E2F4A1B9BDQ28078939-216B7D6F-FE0D-471F-80EE-E9CA24DAC35AQ28086999-16DD1CB0-4ABC-4C82-94DF-0C49B820E6ACQ30369123-77F91BF5-B9B3-49F8-B2E3-2A36E1456828Q33551626-25115913-11DB-4016-8126-EA0E2D342C9BQ33679505-C41E0523-7519-437C-9544-D8EED1273416Q33725706-13F9C1C2-B069-465B-A505-427FE9123F02Q35226511-9D9E9C92-9AD8-48DA-AD0C-65D6BEDD9396Q35541787-11961666-4B50-490D-B960-ECEFCC06916BQ35789319-013143FB-81CD-4DD7-8C1C-5224AFDD87C8Q35861933-81525749-9F36-47D5-BAD4-333060D3D589Q36310887-7DE6CAD2-4E13-4D62-A934-9E8251EE4207Q36464841-4B23F479-15E0-4865-98FD-9056D847FACEQ36549443-4C0661E8-96BE-4C2B-97C2-BA32E49104B4Q36582819-DFE96C3F-2F4B-478D-815F-AE22F71DCF2DQ36664268-D8EE7E1B-2816-4D4E-8FFA-A12711470B9FQ36700481-66A4768B-7A27-42D2-934A-EC68AC6D4296Q36751597-8EA82A46-80DD-4BB9-A257-7CE09465C2DEQ37158473-39D1CBA0-A3B9-4C4E-9876-34603787A575Q37256174-1E36DAA5-1922-44CF-A07D-EF40C732F7E1Q37380398-647998A2-8D8E-4F89-9221-6CDE40552E6AQ37651860-4506308F-918D-4CE7-850A-26C9456F4928Q37736296-6DF6CDF0-5926-4794-98F7-272E02DA4E0EQ38470166-A6531218-5C09-4713-B543-04D267A4A0CBQ38525024-B9A83A08-5F5E-4E8A-9077-FA95B1E781B6Q38534285-D8C463D6-7D2D-4B80-A0A1-7C154FEBDD97Q38611895-A26DA3BD-FE98-4BB8-9E73-7DE5F891B88FQ38612646-D1E7789B-8B11-40DC-8C56-03B4CB87B5A4Q38657642-353ACD3D-5DDE-4CFF-BF42-7EA749D2A1B0Q38676416-4026A210-39E8-4071-A5C6-60B0B74953D8Q38714321-18281885-6155-4D2D-A808-E2AC3C42246DQ38727470-A109741A-F714-4CD5-9F3B-EE4F20171AAEQ38737706-94D74C0B-8085-46A8-B224-694888DCBE3E
P2860
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@ast
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@en
type
label
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@ast
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@en
prefLabel
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@ast
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@en
P2093
P2860
P50
P356
P1433
P1476
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
@en
P2093
Christian Grossardt
Diana Lutz
Dirk Jäger
Dirk M Nettelbeck
Guy Ungerechts
Johanna K Kaufmann
Sascha Bossow
Viktor Umansky
P2860
P304
P356
10.1038/MT.2014.160
P577
2014-08-26T00:00:00Z